Since its establishment, the company has independently developed 7 China-first and World-first vaccine products, and obtained 5 National New Drug Certificates, including 2 First-Class New Drug Certificates; 2 Second-Class National Scientific and Technological Progress Awards and 4 Beijing Scientific and Technological Progress Awards; Undertook 47 national, provincial and ministerial science and technology projects; obtained nearly 60 national invention patents for core technologies, and published more than 120 SCI papers, many of which were published in such top international academic journals as New England Journal of Medicine, The Lancet, Science and Nature etc.